Literature DB >> 24327693

Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment.

Andrew J Rech1, Robert H Vonderheide.   

Abstract

Tumor-infiltrating T cells have recently been found to upregulate immunosuppressive pathways, such as programmed cell death protein 1 ligand 1 (PD-L1), in a paracrine fashion on tumor cells, but tumor cell-intrinsic regulation of PD-L1 is another potential mechanism. In this issue of Cancer Discovery, Akbay and colleagues show that signaling via mutant EGF receptor (EGFR) in murine lung tumor cells directly upregulates tumor PD-L1 and that therapeutic blockade of this pathway improves survival in EGFR-driven preclinical models-highlighting the dynamic interplay and therapeutic opportunities of cancer cell biology and immune biology. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24327693      PMCID: PMC3877936          DOI: 10.1158/2159-8290.CD-13-0775

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  11 in total

1.  Combination checkpoint blockade--taking melanoma immunotherapy to the next level.

Authors:  James L Riley
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

3.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

Authors:  Lauren J Bayne; Gregory L Beatty; Nirag Jhala; Carolyn E Clark; Andrew D Rhim; Ben Z Stanger; Robert H Vonderheide
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

7.  Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.

Authors:  Dietmar M W Zaiss; Jorg van Loosdregt; Andrea Gorlani; Cornelis P J Bekker; Andrea Gröne; Maria Sibilia; Paul M P van Bergen en Henegouwen; Rob C Roovers; Paul J Coffer; Alice J A M Sijts
Journal:  Immunity       Date:  2013-01-17       Impact factor: 31.745

8.  Tumor immune escape by the loss of homeostatic chemokine expression.

Authors:  Andor Pivarcsi; Anja Müller; Andreas Hippe; Juliane Rieker; Anke van Lierop; Martin Steinhoff; Stephan Seeliger; Robert Kubitza; Ulrich Pippirs; Stephan Meller; Peter A Gerber; Ruediger Liersch; Erich Buenemann; Eniko Sonkoly; Ulrike Wiesner; Thomas K Hoffmann; Leonid Schneider; Roland Piekorz; Elaine Enderlein; Julia Reifenberger; Ulrich-Peter Rohr; Rainer Haas; Petra Boukamp; Ingo Haase; Bernd Nürnberg; Thomas Ruzicka; Albert Zlotnik; Bernhard Homey
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-19       Impact factor: 11.205

9.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

Review 10.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

View more
  12 in total

Review 1.  Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

Authors:  David P Carbone; David R Gandara; Scott J Antonia; Christoph Zielinski; Luis Paz-Ares
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

2.  PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.

Authors:  Xiaohui Zhang; Yuanyuan Zeng; Qiuxia Qu; Jianjie Zhu; Zeyi Liu; Weiwei Ning; Hui Zeng; Nan Zhang; Wenwen Du; Cheng Chen; Jian-An Huang
Journal:  Int J Clin Oncol       Date:  2017-07-26       Impact factor: 3.402

Review 3.  Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.

Authors:  Zhong-Yi Dong; Si-Pei Wu; Ri-Qiang Liao; Shu-Mei Huang; Yi-Long Wu
Journal:  Tumour Biol       Date:  2016-01-16

Review 4.  Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition.

Authors:  Janaina Fernandes
Journal:  Biomark Cancer       Date:  2016-07-28

5.  Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature.

Authors:  Aman Chauhan; Millicent Horn; Gray Magee; Kurt Hodges; Mark Evers; Susanne Arnold; Lowell Anthony
Journal:  Oncotarget       Date:  2017-12-28

Review 6.  [Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for 
non-small cell lung cancer].

Authors:  Cheng Lin; Xiong Chen; Jingnan Liu; Yufang Huang; Xuenong Ou-Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-10-20

7.  Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.

Authors:  Shichao Li; Li Chen; Jun Jiang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

Review 8.  Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.

Authors:  Edouard Dantoing; Nicolas Piton; Mathieu Salaün; Luc Thiberville; Florian Guisier
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

Review 9.  Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.

Authors:  Ioannis Zerdes; Alexios Matikas; Jonas Bergh; George Z Rassidakis; Theodoros Foukakis
Journal:  Oncogene       Date:  2018-05-16       Impact factor: 9.867

10.  ZFPM2-AS1 promotes the proliferation, migration, and invasion of human non-small cell lung cancer cells involving the JAK-STAT and AKT pathways.

Authors:  Xiwen Wang; Jun Tang; Jungang Zhao; Bin Lou; Li Li
Journal:  PeerJ       Date:  2020-10-26       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.